Evidence map›Paper›PMID 29700127›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018

Jiang Wu, Shaohua Wang, Xianzhong Zhang, Zhaogang Teng, Jingjie Wang, Bryant C Yung, Gang Niu, Hong Zhu, Guangming Lu, Xiaoyuan Chen

Abstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Prospective Phase II Trial of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Trial
  3. Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026
    Review
  4. Head-to-head evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  5. Review
  6. Review
  7. Micronutrient Status and Breast Cancer: A Narrative Review.International journal of molecular sciences · 2024
    Review
  8. A comparison of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  9. Review
  10. The Role of PET/CT in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023
    Review
  11. Review
  12. Theranostics in breast cancer.Frontiers in nuclear medicine · 2023
    Review
  13. Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  14. First-in-Human Study of [Diagnostics (Basel, Switzerland) · 2022
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. The aluminium-[EJNMMI radiopharmacy and chemistry · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiang WuDepartment of Nuclear Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Shaohua WangDepartment of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Xianzhong ZhangCenter for Molecular Imaging and Translational Medicine, Xiamen University, Xiamen, China.
Zhaogang TengDepartment of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China; and.
Jingjie WangDepartment of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Bryant C YungLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.
Gang NiuLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.
Hong ZhuDepartment of Nuclear Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Guangming LuDepartment of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China; and shawn.chen@nih.gov cjr.luguangming@vip.163.com.
Xiaoyuan ChenLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland shawn.chen@nih.gov cjr.luguangming@vip.163.com.

Funding

Laboratory of Molecular Imaging and NanomedicineZIAEB000073 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CHEN, XIAOYUAN · 2010 to 2020
$32.8M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Fluorodeoxyglucose F18Peptides, CyclicAdultAgedBreast NeoplasmsDouble-Blind MethodErb-b2 Receptor Tyrosine KinasesFalse Positive ReactionsFemaleFluorine RadioisotopesHumansMiddle AgedPositron Emission Tomography Computed TomographyRadiopharmaceuticalsTriple Negative Breast Neoplasmsalfatide IIERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorine RadioisotopesFluorodeoxyglucose F18Peptides, CyclicRadiopharmaceuticals18F-alfatide IIbreast cancerintegrin αvβ3positron emission tomography

Identifiers

PMID29700127
PMCPMC6910641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.